Lanctôt KL - Search Results

1

Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T, Lanctôt KL. Swardfager W, et al. Among authors: lanctot kl. Biol Psychiatry. 2013 Dec 15;74(12):872-8. doi: 10.1016/j.biopsych.2013.05.008. Epub 2013 Jun 24. Biol Psychiatry. 2013. PMID: 23806573

2

Utility scores of symptom profiles in major depression.

Schaffer A, Levitt AJ, Hershkop SK, Oh P, MacDonald C, Lanctot K. Schaffer A, et al. Psychiatry Res. 2002 Jun 1;110(2):189-97. doi: 10.1016/s0165-1781(02)00097-5. Psychiatry Res. 2002. PMID: 12057830

3

Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease.

Lanctôt KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA. Lanctôt KL, et al. Int J Geriatr Psychiatry. 2002 Jun;17(6):531-41. doi: 10.1002/gps.636. Int J Geriatr Psychiatry. 2002. PMID: 12112177 Clinical Trial.

4

Central serotonergic activity is related to the aggressive behaviors of Alzheimer's disease.

Lanctôt KL, Herrmann N, Eryavec G, van Reekum R, Reed K, Naranjo CA. Lanctôt KL, et al. Neuropsychopharmacology. 2002 Oct;27(4):646-54. doi: 10.1016/s0893-133x(02)00339-1. Neuropsychopharmacology. 2002. PMID: 12377401

5

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.

Lanctôt KL, Herrmann N, LouLou MM. Lanctôt KL, et al. J Psychiatry Neurosci. 2003 Jan;28(1):13-26. J Psychiatry Neurosci. 2003. PMID: 12587847 Free PMC article. Review.

6

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR. Lanctôt KL, et al. CMAJ. 2003 Sep 16;169(6):557-64. CMAJ. 2003. PMID: 12975222 Free PMC article. Review.

7

The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.

Wu G, Lanctôt KL, Herrmann N, Moosa S, Oh PI. Wu G, et al. Among authors: lanctot kl. CNS Drugs. 2003;17(14):1045-57. doi: 10.2165/00023210-200317140-00004. CNS Drugs. 2003. PMID: 14594444

8

Atypical antipsychotics and risk of cerebrovascular accidents.

Herrmann N, Mamdani M, Lanctôt KL. Herrmann N, et al. Among authors: lanctot kl. Am J Psychiatry. 2004 Jun;161(6):1113-5. doi: 10.1176/appi.ajp.161.6.1113. Am J Psychiatry. 2004. PMID: 15169702

9

Growth hormone response to clonidine predicts aggression in Alzheimer's disease.

Herrmann N, Lanctôt KL, Eryavec G, Van Reekum R, Khan LR. Herrmann N, et al. Among authors: lanctot kl. Psychoneuroendocrinology. 2004 Oct;29(9):1192-7. doi: 10.1016/j.psyneuen.2004.02.001. Psychoneuroendocrinology. 2004. PMID: 15219643 Clinical Trial.

10

Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients.

Herrmann N, Lanctôt KL, Eryavec G, Khan LR. Herrmann N, et al. Among authors: lanctot kl. J Psychopharmacol. 2004 Jun;18(2):215-20. doi: 10.1177/0269881104042625. J Psychopharmacol. 2004. PMID: 15260910 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

349 results

Search Page

Filters